Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
Keywords: Alzheimer's disease; benzodiazepines; cognition; dementia; risk factors.
Copyright © 2020 Ettcheto, Olloquequi, Sánchez-López, Busquets, Cano, Manzine, Beas-Zarate, Castro-Torres, García, Bulló, Auladell, Folch and Camins.
Association of benzodiazepine and Z-drug use with the risk of hospitalisation for fall-related injuries among older people: a nationwide nested case-control study in Taiwan.BMC Geriatr. 2017 Jul 11;17(1):140. doi: 10.1186/s12877-017-0530-4. BMC Geriatr. 2017. PMID: 28693443 Free PMC article.
Pharmacotherapies for sleep disturbances in Alzheimer's disease.Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178. doi: 10.1002/14651858.CD009178.pub2. Cochrane Database Syst Rev. 2014. PMID: 24659320 Updated. Review.
Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use.Neurotherapeutics. 2020 Jan;17(1):156-164. doi: 10.1007/s13311-019-00801-9. Neurotherapeutics. 2020. PMID: 31802436
Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries.Eur J Clin Pharmacol. 2013 Apr;69(4):1-10. doi: 10.1007/s00228-012-1424-1. Epub 2012 Nov 1. Eur J Clin Pharmacol. 2013. PMID: 23114457 Free PMC article.
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. Swedish Council on Health Technology Assessment (SBU). 2008. PMID: 28876770 Free Books & Documents. Review.